Biotechnology firm Silence Therapeutics is to tap the market, offering shares at a sharp discount, as it seeks to bolster its balance sheet.
The group plans to raise up to £5.7m before expenses through the issue of 940m new shares at a halfpenny each and a £1m convertible loan note issue.
Of the newly issued ordinary shares, 840m will be made available through subscription to certain investors and directors, with the rest up for grabs in an open offer.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The issue price represents a discount of around 44% to the closing price of ordinary shares on Wednesday, the day before the fund raising was announced. The issue has not been underwritten.
The firm also disclosed that it has entered into a £10m equity finance facility with Darwin Strategic, a subsidiary of Alphagen Volantis Fund, part of the fund management group Henderson Global Investors.
"Over the next two years we expect to conclude multiple value-driving events including completion of a second clinical trial of Atu027. The proceeds from this fund-raising will strengthen the balance sheet with a view to ensuring that Silence extracts the highest value from its products and RNAi technology platform," said company Chairman Jerry Randall.
RNAi stands for RNA interference, sometimes called gene silencing.
Silence Therapeutics fell 12p to 0.77p by 11:06.
NR
-
Buying a property is cheaper than renting again – how much could you save?News Zoopla research shows it is now 8% cheaper to buy than rent. We reveal the places where you can save more by getting on the property ladder.
-
Is now a good time to invest in India?Should you invest in India? Its market has stood out of the emerging market pack, helped by a growing pool of domestic investors.
